In an interview on the first-in-human phase 1 study of gintemetostat, Saad Z. Usmani, MD, PhD, detailed the initial safety ...

FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable ...

For many patients undergoing cancer treatment, hair loss is one of the most distressing adverse effects. In an effort to take ...

New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter.

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...

The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...

In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.

The central finding was the superior activity of a 2-antibody combination against the type 1 mutant CALR neoantigen. Dual ...

SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable ...

Pellini notes that Hispanic patients often exhibit a higher incidence of specific genomic alterations in their cancers.

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at nearly 3 years, according ...